Partners

Clinical Partners

Clinical and Scientific Consortium, Distinguished Members

W. Randolph Chitwood, Jr. M.D.
Emeritus Professor and Chairman, Department of Surgery; Emeritus Professor, Department of Cardiovascular Studies;
Brody School of Medicine, East Carolina University
Greenville, NC

Joseph DeSimone, PhD
Chancellor’s Eminent Professor of Chemistry, University of North Carolina at Chapel Hill;
William R. Kenan, Jr. Distinguished Professor of Chemical Engineering, North Carolina State University
Chapel Hill, NC

Pascal J. Goldschmidt, M.D.
University of Miami Leonard M. Miller School of Medicine;  Advisor of International Medical Education; University of Miami Health System
Miami, Fl

Joseph C Greenfield, Jr., M.D.
Chief of Cardiology Emeritus, Duke University Medical Center
Durham, NC

James B Hermiller, Jr., M.D., FACC, FSCAI
Director of Interventional Cardiology and Interventional Cardiology Fellowship Director, St.Vincent Heart Center of Indiana
Indianapolis, IN

Andy C. Kiser, M.D., FACS, FACC, FCCP
John Mark Williams, MD Distinguished Professor in Cardiac Surgery
Chief, Division of Cardiac Surgery
East Carolina Heart Institute; East Carolina University
Greenville, NC

William Knopf, M.D.
Chief, Cardiovascular Services
St. Vincent Healthcare
Billings, MT

William O’Neill, M.D., F.A.C.C., F.S.C.A.I.
Medical Director, Center for Structural Heart Disease, Henry Ford Hospital,
Detroit, MI

Harry R Phillips, M.D.
Professor of Medicine, Associate Director, Duke Heart Center; Chief Medical Officer, Duke Network Services, Duke University Medical Center,
Durham ,NC

Gary S. Roubin, M.D., FACC, PhD
Medical Director; Cardiovascular Associates
Chief of Cardiology; Brookwood Baptist Medical Center
Birmingham, AL

Barry D Rutherford, M.D., FACC
Associate Professor of Medicine, University of Missouri – Kansas
City School of Medicine
Kansas City, MO

Thomas J Ryan, M.D.
Director, Ohio State University Heart and Vascular Center
Professor of Cardiovascular Medicine, Ohio State Medical Center,
Columbus, OH

Judith Swain, M.D.
Executive Director, Singapore Institute for Clinical Sciences within A*STAR
Lien Chow Professor of Medicine, National University of Singapore
Singapore

H. Lee Sweeney, PhD.
William Maul Measey Professor
Chairman of Physiology, Department of Physiology
University of Pennsylvania,
Philadelphia, PA

Renu Virmani, M.D., FACC
President, Medical Director, CVPath Institute,
Gaithersburg, MD

Paul Yock, M.D.
Martha Meier Weiland Professor of Medicine
Director, Biodesign; Founding Co-Chair , Department of Bioengineering
Stanford University,
Stanford, CA

Financial Partners

synergy

About Synergy Life Science Partners: Synergy Life Science Partners is a venture capital firm that focuses on investing in private, early stage medical device companies or emerging companies who are combining a medical device with a therapeutic payload (drugs, biologics, etc.) — the “combination product” opportunities. synergylsp.com

abv

About Ascent Biomedical Ventures: Ascent Biomedical Ventures (ABV) is a venture capital firm investing in seed and early-stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. ABV’s principals and advisors work closely with entrepreneurs to manage the risks associated with deploying capital in startup companies. abvlp.com

abbott

About Abbott Vascular: Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on transforming the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. abbottvascular.com

jnj

About Johnson & Johnson Development Corporation: Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies. jjdevcorp.com

Medtronic

About Medtronic Inc: Medtronic is the world’s largest medical technology company, offering an unprecedented breadth and depth of innovative therapies to fulfill our Mission of alleviating pain, restoring health, and extending life. Last year, more than 9 million people benefited from our medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions. With a global reach that extends to more than 140 countries, we have a deep understanding of many universal healthcare challenges. We’re using our experience, extensive partnerships, and the passion of 46,000+ employees to help transform healthcare worldwide by improving outcomes, expanding access, and enhancing value.

Piedmont2

About Piedmont Capital Partners, LLC: Piedmont Capital Partners is a boutique investment firm with offices in Greensboro, North Carolina. We focus on early stage North Carolina companies and entrepreneurs.

Industrial Partners

abbott

About Abbott Vascular: Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on transforming the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education.

abbottvascular.com

ge

About GE Medical Systems: GE Medical Systems is a $7 billion global leader in medical systems, information and technology. Its offerings include networking and productivity tools, healthcare information systems, patient-monitoring systems, conventional and digital X-ray, computed tomography (CT), magnetic resonance (MR), ultrasound, positron emission tomography (PET), and nuclear medicine systems. With global headquarters in Waukesha, Wisconsin, healthcare providers worldwide rely on GE Medical Systems for high quality medical technology, services and productivity solutions.

gemedicalsystems.com

jnj

About Johnson & Johnson Development Corporation: Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies. jjdevcorp.com

Medtronic

About Medtronic Inc: Medtronic is the world’s largest medical technology company, offering an unprecedented breadth and depth of innovative therapies to fulfill our Mission of alleviating pain, restoring health, and extending life. Last year, more than 9 million people benefited from our medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions. With a global reach that extends to more than 140 countries, we have a deep understanding of many universal healthcare challenges. We’re using our experience, extensive partnerships, and the passion of 46,000+ employees to help transform healthcare worldwide by improving outcomes, expanding access, and enhancing value.

Boston Scientific

About Boston Scientific: Our products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health, and chronic pain conditions. We continue to innovate in these areas and are extending our innovations into new geographies and high-growth adjacency markets.

Management Partners

Board of Directors

Richard S. Stack, M.D., F.A.C.C., Synecor

Open Bio

Dr. Richard S. Stack is President of Synecor, LLC (Synecor) a business generator and financial incubator of new medical device companies based in the Research Triangle Park, North Carolina. He is also General Partner of Synergy Life Science Partners, LP (www.synergylsp.com) a life science venture fund. In the past ten years, Richard has co-founded and invested in eight major medical device companies, including Synecor itself, with a combined current valuation of over $675M. Richard chairs the scientific advisory board, leads the pre-clinical testing services provided at Synecor and is the interim President of each of the Synecor spinout companies.

Richard has long been recognized as an international thought leader in the medical technology field. He has authored over 360 manuscripts, book chapters and scientific abstracts. He has been a principal and co-principal investigator of three NIH grants and received numerous research awards during his career including the International Award for Best Interventional Cardiology Experimental Research (1995, Netherlands). Richard has invented and/or invested in numerous technologies that have become adopted by physicians the world over. He has over 100 worldwide patents issued or pending on a wide variety of medical devices.

Richard is Professor Emeritus of Medicine in Cardiology at Duke University in Durham, North Carolina, where he spent his entire academic medical career, since 1981, as Founder and Director of Duke Interventional Cardiology. Richard retired early from his academic career to join the investment community with the formation of Synecor, LLC in the year 2000 and Synergy LSP in 2006.

William N. Starling, Synecor

Open Bio

William N. Starling is Managing Director of Synergy Life Science Partners, LP (www.synergylsp.com) a $143 million Venture Capital Partnership and Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field.

As CEO of Synecor, Mr. Starling is a cofounder of BaroSense, Inc., Bioerodible Vascular Solutions, Inc., (BVS, acquired by Guidant/Abbott in March 2003), InnerPulse, Inc., TransEnterix, Inc. (NYSE:TRXC), Interventional Autonomics Corporation, NeuroTronik Limited, Aegis Surgical Limited, Atrius Limited, and Ventrius, Inc. the initial nine companies founded and incubated by Synecor. Mr. Starling currently serves as CEO of Aegis Surgical Limited, and Atrius Limited, both Irish-based companies in the structural heart field; CEO of Ventrius, Inc. in the heart failure field, and as a board member of TransEnterix, Inc. (NYSE: TRXC), a RTP, NC – based robotic surgery company pioneering digital laparoscopic robotic surgery worldwide. Mr. Starling was on the Board of iRhythm Technologies, Inc. (NASDAQ: IRTC) in San Francisco, a Stanford BioDesign spinout, since its inception in January 2007 until its initial public offering October 20, 2016. Mr. Starling is Chairman of the Board of RTP, NC – based InnAVasc, Inc., an early stage startup company spun out of Duke University engaged in the development of improved renal dialysis technology.

William N. Starling received his BSBA degree from the University of North Carolina at Chapel Hill and his MBA degree from the University of Southern California. He began his 41-year career in the medical technology device industry at American Edwards Laboratories (Edwards LifeSciences – NYSE:EW). He was subsequently part of the founding management team and Director of Marketing for Advanced Cardiovascular Systems, Inc. (acquired by Guidant/Abbott), and was cofounder, Vice President and Board member of Ventritex, Inc. (IPO in 1992, acquired by St. Jude Medical/Abbott in 1997). Mr. Starling was cofounder and Chairman of the Board of Directors and President/CEO of Cardiac Pathways Corporation (IPO in 1996, acquired by Boston Scientific Corporation in 2001). The start-up companies he has co-founded today represent over $4 billion in annual revenues and Mr. Starling is responsible for raising over $275M in private and public capital for these development stage companies.

Mr. Starling serves on the Stanford Stroke Center’s Board of Advisors at the Stanford University Medical Center. He also serves on the Kenan-Flagler Business School Board of Visitors (Chairman 2009-2014), Chairman of the UNC/NCSU Department of Biomedical Engineering Industry Advisory Board and the Chancellor’s Innovation Circle at the University of North Carolina at Chapel Hill where he frequently guest lectures to undergraduate and graduate students on entrepreneurism. Mr. Starling is the recipient of the 2016 UNC Kenan-Flagler Leadership Award, awarded annually to an alumnus for exceptional achievement in a career field, personal endeavor or service to UNC Kenan-Flagler.

H. Michael Cohen, Deutsche Bank

Steve Hochberg, Deerfield Management

William Knopf, M.D., St. Vincent Healthcare

R. Frederick McCoy, Jr., NeuroTronik, Inc.

Open Bio

Fred McCoy, Vice Chairman of Synecor, LLC (www.synecor.com), is CEO of NeuroTronik Limited, founded on technology of Synecor and Interventional Autonomics Corporation and domiciled in Ireland. NeuroTronik, now a venture-backed, development-stage company, exists to develop and commercialize a novel neuromodulation therapy, for use in hospitals, to treat acute heart failure. The objectives are to improve clinical and economic outcomes for patients, physicians, hospitals, and payers.

A native of Laurinburg, North Carolina, Mr. McCoy graduated as a Bachelor of Science in Business Administration from the University of North Carolina at Chapel Hill in 1979. He graduated as a Master of Management from the Northwestern University J.L. Kellogg Graduate School of Management in 1981.

Mr. McCoy began his business career with Eli Lilly and Company in Indianapolis, Indiana. There he worked in a series of assignments of increasing responsibility in finance in the corporate, domestic, international, pharmaceutical, and agricultural businesses of the Company. During part of this early period, he also served as a pharmaceutical sales representative in Montgomery, Alabama.

In 1988, Mr. McCoy became Vice President of Finance of Hybritech Incorporated, a Lilly subsidiary, in San Diego, California. In 1991, he became Chief Financial Officer of Cardiac Pacemakers, Inc., a Lilly subsidiary, in Saint Paul, Minnesota.

Mr. McCoy entered general management in 1994 as General Manager, Northwest Operations, in Seattle, Washington. Later in 1994, Guidant Corporation was formed out of the medical technology enterprises of Lilly. In 1995, Mr. McCoy became Vice President of United States Operations – West.

In 1997, he moved to Tokyo, Japan as President, Guidant Japan and Asia Pacific Operations.

In 2000, Mr. McCoy became President, Guidant Cardiac Rhythm Management, in Saint Paul, Minnesota, where he served until March 2006 pending the sale of the Company.

Mr. McCoy is a member of the Boards of Directors of NeuroTronik, Synecor, Interventional Autonomics Corporation, and Physcient. He is advisor to several emerging companies in medical technology. He serves on the Boards of Trustees of Webber International University and of St. Andrews University. He has served on the Board of Visitors and on the Chancellor’s Innovation Circle, both of the University of North Carolina at Chapel Hill. He has served as a member of the Kellogg Alumni Council of the Kellogg School at Northwestern University.

Mudit Jain, Synergy Life Science Partners, LP

Robert Taber, Ph.D.

Daniel Sheehan, Medtronic, Inc.

Kadir Kadhiresan, Johnson & Johnson Development Corp.

Executive Committee

Richard S. Stack, M.D., F.A.C.C., Synecor

William N. Starling, Synecor

Steve Hochberg, Deerfield Management

Daniel Sheehan, Medtronic, Inc.

Ray Larkin, former CEO of Nellcor Inc.

Mudit Jain, Synergy Life Science Partners, LP

Kadir Kadhiresan, Johnson & Johnson Development Corp.